Next Article in Journal
Is Fasting Good When One Is at Risk of Liver Cancer?
Next Article in Special Issue
Hepatocellular Carcinoma Recurrence and Mortality Rate Post Liver Transplantation: Meta-Analysis and Systematic Review of Real-World Evidence
Previous Article in Journal
Mediating Effects of Diagnostic Route on the Comorbidity Gap in Survival of Patients with Diffuse Large B-Cell or Follicular Lymphoma in England
Previous Article in Special Issue
Surgical Resection Is Superior to TACE in the Treatment of HCC in a Well Selected Cohort of BCLC-B Elderly Patients—A Retrospective Observational Study
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Cancers
Volume 14
Issue 20
10.3390/cancers14205083
Review Report
cancers-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Article
Peer-Review Record

Modified Albumin–Bilirubin Model for Stratifying Survival in Patients with Hepatocellular Carcinoma Receiving Anticancer Therapy

Cancers 2022, 14(20), 5083; https://doi.org/10.3390/cancers14205083
by Wei-Fan Hsu 1,2,3, Shih-Chao Hsu 4, Te-Hong Chen 4, Chien-Hung Lin 5, Ying-Chun Lin 6, Yu-Wei Chang 7, Hung-Wei Wang 1,8, Yu-Min Liao 9, Hsueh-Chou Lai 1,3 and Cheng-Yuan Peng 1,8,*
Reviewer 1:
Shigeo Shimose
Reviewer 2:
Mahesh Gokara
Cancers 2022, 14(20), 5083; https://doi.org/10.3390/cancers14205083
Submission received: 17 September 2022 / Revised: 9 October 2022 / Accepted: 15 October 2022 / Published: 17 October 2022
(This article belongs to the Collection Advances in the Management of Hepatocellular Carcinoma)

Round 1

Reviewer 1 Report

The author reported that new modified ALBI grade ;”ALBI score ≤-3.02 for mALBI grade 1, an ALBI score >-3.02 to ≤-2.08 for mALBI grade 2, and an ALBI score >-2.08 for mALBI grade 3” for HCC patients. This report is an interesting perspective. However, there were serious problems in this manuscript.

Currently, HCC was diagnosed at the advanced HCC stage, and treatment strategies are particularly important in these populations. Therefore, the original ALBI system divides ALBI grade 2 into modified ALBI 2a or modified ALBI 2b. I think ALBI garde2 in this study has a very wide range from -3.02 to -2.08. Moreover, patients who receive systemic therapy often fall within these ranges. Thus, the author should analyze using modified ALBI grade 2a or 2b, not the original ALBI grade 2. Or can the newly modified ALBI grade 2 in this study be further subdivided statistically?

Author Response

Please see the attachment.

Author Response File: Author Response.docx

Reviewer 2 Report

The article by Cheng-Yuan Peng et al, entitled ‘’ Modified albumin–bilirubin model for stratifying survival in patients with hepatocellular carcinoma receiving anticancer therapy “describes the mALBI model which can differentiate between patients with early, intermediate, or advanced HCC who received anticancer therapy. The overall manuscript is well written, the study will certainly expand our knowledge on albumin-based models in cancer therapy. There are no major points for this work. with the incorporation of the following minor change, I would enthusiastically endorse the publication of this article in Cancers.

 Please improve the quality of the figures, especially the font type size to make them more legible.

 

 

 

Author Response

Please see the attachment.

Author Response File: Author Response.docx

Round 2

Reviewer 1 Report

This submitted paper has been appropriately refined according to the reviewer's advice.

Back to TopTop